CSPC Pharmaceutical Group Limited obtains NMPA clinical trial approval for TF-targeted ADC SYS6051 in China

CAR-T Digest - August 2020

15 April 2026: CSPC Pharmaceutical Group Limited obtains NMPA clinical trial approval for TF-targeted ADC SYS6051 in China

CSPC Pharmaceutical Group Limited has received clinical trial approval in China for SYS6051, a tissue factor targeted ADC, marking progress in the development of its oncology pipeline
This approval enables the company to initiate clinical studies in China, advancing SYS6051 into the clinical stage and expanding its portfolio of innovative biologics for cancer treatment
SYS6051 is designed to target tissue factor expressed on tumor cell surfaces, allowing internalization into cancer cells and release of cytotoxic payloads to induce tumor cell death
Preclinical studies have demonstrated promising antitumor activity across multiple solid tumor types, supporting its potential therapeutic benefit in a broad range of cancers
The product is expected to exhibit favorable therapeutic effects in subsequent clinical trials